



Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/048,046
				Filing Date	January 24, 2002
				First Named Inventor	Halazonetis et al.
				Group Art Unit	1642
				Examiner Name	M. Davis
Sheet	1	of	1	Attorney Docket Number	WST97AUSA

NONPATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
JD	BV	HALAZONETIS, T.D., "Constitutively active DNA damage checkpoint pathways as the driving force for the high frequency of p53 mutations in human cancer", <i>DNA Repair (Amst)</i> . Aug.-Sept. 2004 3(8-9):1057-1062		
	BW	HUYEN et al., "Structural differences in the DNA binding domains of human p53 and its <i>C. elegans</i> ortholog Cep-1", <i>Structure (Camb)</i> . July 2004 12(7):1237-1243		
	BX	MARIATOS et al., "Inactivating mutations targeting the <i>chfr</i> mitotic checkpoint gene in human lung cancer", <i>Cancer Res</i> . November 1, 2003 63(21): 7185-7189		
	BY	MOCHAN et al., "53BP1, an activator of ATM in response to DNA damage", <i>DNA Repair (Amst)</i> . Aug.-Sept. 2004 3(8-9):945-952		
	BZ	MOCHAN et al., "53BP1 and NFBDI/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage", <i>Cancer Res</i> . December 15, 2003 63(24): 8586-8591		
	CR	STAVRIDIS et al., "p53 and stress in the ER", <i>Genes Dev</i> . February 1, 2004 18(3):241-244		
	CS	VENERE et al., "Chk2 leaves the PML depot", <i>Nature Cell Biol</i> . November 2002 4(11):E255-E256		

Examiner Signature	M. T. DAVIS	Date Considered	02/02/05
--------------------	-------------	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.